The JOURNAL OF DERMATOLOGICAL TREATMENT, published by TAYLOR & FRANCIS LTD, is a premier forum dedicated to advancing the field of dermatology through the dissemination of high-quality research. Since its inception in 1989, this journal has maintained a significant impact on the dermatological community, currently ranking in the top quartile (Q1) of the Dermatology category with an impressive Scopus ranking of #14 out of 142 journals, reflecting its reputation among peers and its contribution to the clinical and academic landscape. The journal shifted to Open Access in 2023, enhancing the accessibility of groundbreaking findings to researchers, clinicians, and students worldwide. With a commitment to publishing diverse articles, from innovative treatment modalities to comprehensive reviews, the JOURNAL OF DERMATOLOGICAL TREATMENT serves as an invaluable resource for professionals seeking to stay at the forefront of dermatological science in a rapidly evolving field.

ANAIS BRASILEIROS DE DERMATOLOGIA is a prestigious academic journal published by Elsevier Science Inc, specializing in the dynamic field of dermatology. With its Open Access model established in 2002, this journal ensures wide dissemination of research findings and facilitates collaboration within the dermatological community. Hailing from Brazil, it provides a platform for innovative research from both local and international contributors, spanning from its inception in 1963 to the current year, 2024. The journal positions itself as a vital resource in the dermatology sphere, currently ranked in the Q3 category for dermatology and holding a notable rank of 71 out of 142 in the Scopus rankings, placing it in the 50th percentile for its field. With a commitment to advancing knowledge and practice in dermatology, ANAIS BRASILEIROS DE DERMATOLOGIA is an essential read for researchers, professionals, and students eager to explore contemporary advancements and clinical practices.

Journal of Drugs in Dermatology, an esteemed publication in the field of dermatology, serves as a vital resource for researchers, clinicians, and healthcare professionals dedicated to advancing knowledge and practices in skin-related therapies and treatments. Established in 2002 and published in the United States, this journal focuses on a wide range of topics pertinent to dermatological pharmacology and therapeutics, reflecting contemporary scientific advancements and innovative approaches to patient care. With a strong presence in Scopus rankings, situating it at rank #73 within the dermatology category, and achieving a commendable Q2 quartile classification in both dermatology and general medicine categories, the journal is committed to enhancing understanding of drug efficacy and safety in dermatological conditions. While the journal maintains a traditional access model, its impact factor underscores its significance in the research community, supporting the ongoing dialogue between academia and clinical practice. We invite professionals and students alike to explore the latest findings and contribute to the progressive discourse on dermatological treatments through this important publication.

The British Journal of Dermatology, published by Oxford University Press, stands as a premier platform for advancing the field of dermatological research and clinical practice since its inception in 1892. With a strong commitment to disseminating high-quality research, this esteemed journal is currently ranked in the Q1 category for both Dermatology and Miscellaneous Medicine in 2023, reflecting its influential position in the academic landscape. As the leading journal in its field, it enjoys a robust Scopus ranking of #1 out of 142 in dermatology, placing it in the 99th percentile globally. The journal covers a wide scope of subjects pertinent to dermatology, including clinical trials, treatment innovations, and epidemiological studies, making it an essential resource for researchers, healthcare professionals, and students alike. Although it is not an open-access publication, it ensures a broad reach through institutional subscriptions, fostering knowledge exchange across the global dermatological community. Based in the heart of the United Kingdom, the British Journal of Dermatology continues to play a crucial role in shaping the future of skin health and disease management.

Indian Journal of Paediatric Dermatology (ISSN: 2319-7250; E-ISSN: 2319-7269), published by Wolters Kluwer Medknow Publications, stands as a pivotal resource in the specialized field of paediatric dermatology. As a peer-reviewed open access journal since 2013, it aims to disseminate cutting-edge research, clinical practices, and innovative developments that cater to the specific dermatological needs of children. The journal provides an essential forum for collaboration among researchers, clinicians, and students, facilitating the sharing of knowledge on a wide array of topics, including skin conditions unique to paediatric populations, treatment methodologies, and advancements in dermatological care. With a commitment to enhancing the understanding and treatment of paediatric skin diseases, this journal plays a critical role in shaping best practices and informing future research directions in a rapidly evolving field.

Journal of Dermatology & Dermatologic Surgery (JDDS) is a premier open access journal published by Wolters Kluwer Medknow Publications since 2018. This journal serves as a vital platform for the dissemination of cutting-edge research and advancements in the field of dermatology and dermatologic surgery. With its ISSN 2352-2410 and E-ISSN 2352-2429, JDDS strives to present high-quality articles that encompass clinical studies, innovative surgical techniques, and comprehensive reviews, thereby catering to the interests of researchers, medical professionals, and students alike. The journal has gained recognition within the academic community, evidenced by its Scopus ranks, placing it 237th out of 551 in the Medicine - Surgery category and 70th out of 142 in Medicine - Dermatology. The open access model not only enhances visibility but also encourages global collaboration and knowledge sharing in the rapidly evolving field of dermatology. Targeting the needs of diverse audiences, JDDS continues to foster an environment for scholarly communication and contributes significantly to the advancement of dermatologic sciences.

Actas Dermo-Sifiliograficas, published by Elsevier España, stands as a pivotal resource in the realms of dermatology, histology, and pathology and forensic medicine. With its ISSN of 0001-7310 and E-ISSN 1578-2190, this esteemed journal has transitioned to an Open Access model since 2020, facilitating broader dissemination of impactful research. Operating from its Madrid headquarters, it has been a vital platform for scholarly exchange since its inception in 1945, continuing through its converged years until 2024. The journal holds a Q3 ranking in dermatology, histology, and pathology and forensic medicine as of 2023, reflecting its relevance in the academic community where it ranks 79th in dermatology and 126th in pathology among its peers. With a commitment to advancing knowledge and practice in its fields, Actas Dermo-Sifiliograficas serves as an essential repository for researchers, professionals, and students seeking to engage with the latest findings and innovative perspectives in skin and disease research.

The Journal of Cutaneous Immunology and Allergy, published by FRONTIERS MEDIA SA in Switzerland, is an esteemed Open Access platform dedicated to advancing research in the intersecting fields of dermatology, immunology, and allergy. Since its inception in 2018, this journal has provided a vital resource for the dissemination of innovative research findings and critical reviews, enhancing our understanding of cutaneous conditions related to immune responses. Although currently classified in the Q4 quartile in both Dermatology and Immunology & Allergy categories as of 2023, the journal continues to strive for recognition within the scientific community, encouraging collaboration and knowledge sharing among researchers, clinicians, and experts. The journal boasts an E-ISSN of 2574-4593 and is committed to making high-quality research freely accessible to all, thus fostering greater insights into the complexities of skin-related immune disorders. Join us in this journey to explore the forefront of cutaneous research and contribute to the evolving dialogue in this dynamic field.

Dermatologica Sinica, published by Wolters Kluwer Medknow Publications, is an esteemed open-access journal in the field of dermatology that has been disseminating critical research since its inception in 2005. With an E-ISSN of 2223-330X and an ISSN of 1027-8117, this journal presents a platform for researchers, clinicians, and students to share cutting-edge findings and advancements in dermatological science. As of 2023, it proudly ranks in the Q2 category of dermatology journals and holds a notable position at rank #62 out of 142 in the Scopus Medicine - Dermatology category, placing it in the 56th percentile for impact. The journal transitioned to an open-access model in 2016, enhancing accessibility and visibility for groundbreaking studies worldwide. With a commitment to fostering innovation in the dermatological community, Dermatologica Sinica aims to advance the understanding and treatment of skin diseases while encouraging scholarly dialogue among practitioners and researchers across the globe.

Dermatitis, published by MARY ANN LIEBERT, INC, is a leading journal that focuses on the study of skin inflammation and allergic reactions, making significant contributions to the fields of Dermatology, Immunology, and Allergy. With an ISSN of 1710-3568 and an E-ISSN of 2162-5220, this peer-reviewed journal serves as a critical platform for researchers, healthcare professionals, and students alike, eager to share and explore groundbreaking findings and developments. Recognized for its impact and rigorous scholarly standards, Dermatitis has achieved a Q2 quartile ranking in dermatology and a Q3 ranking in immunology and allergy as of 2023, underscoring its significance in these vital medical sectors. The journal's Scopus ranking places it in the 84th percentile for dermatology and the 50th percentile for immunology and allergy, reflecting its wide acceptance and influence. With a scope spanning from 2004 to 2024, Dermatitis invites original research, reviews, and clinical updates that advance the understanding of skin disorders and therapy innovations, solidifying its role as an essential resource in enhancing skin health worldwide.